Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Eur J Clin Pharmacol ; 77(2): 215-221, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33000414

ABSTRACT

PURPOSE: Zuclopenthixol is an antipsychotic available as oral and long-acting injectable (LAI) formulations. The aim of this study was to investigate the effect of age on zuclopenthixol exposure during oral and LAI administrations without and with adjustment for CYP2D6 genotype. METHODS: Data on serum concentrations of zuclopenthixol and CYP2D6 genotype (available for 28.2% of the population) from patients using oral or LAI zuclopenthixol were included retrospectively from a therapeutic drug monitoring service during the period 2005-2019. As a measure of exposure, dose-adjusted serum concentration (C/D ratio) was used. Based on age, patients were grouped to older (≥ 65 years) or younger (18-64 years). Linear mixed model analyses without and with adjustment for CYP2D6 genotype were used. RESULTS: Serum concentrations of zuclopenthixol from 1145 (14.1% older) and 899 patients (24.6% older) in the LAI and oral groups were included, respectively. Compared with younger patients, older patients had a higher C/D ratio of zuclopenthixol for LAI (+ 25-33%, p < 0.001) and oral formulation (+ 25-29%, p ≤ 0.003) without and with adjustment for CYP2D6 genotype. The doses were lower in older versus younger patients (oral: - 30%; LAI: - 20%; p < 0.001). Compared with the younger LAI users without reduced CYP2D6 function, a higher C/D ratio was observed in the older LAI users with reduced CYP2D6 function (+ 104%, p < 0.001). CONCLUSION: The present study showed that zuclopenthixol exposure increases in older patients and that the older LAI users with reduced CYP2D6 function are exposed to high serum concentrations. Also, the present study showed that similar dose reductions are required for oral and LAI users.


Subject(s)
Antipsychotic Agents/pharmacokinetics , Clopenthixol/pharmacokinetics , Cytochrome P-450 CYP2D6/genetics , Schizophrenia/drug therapy , Administration, Oral , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antipsychotic Agents/administration & dosage , Clopenthixol/administration & dosage , Cytochrome P-450 CYP2D6/metabolism , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Female , Humans , Injections , Male , Middle Aged , Norway , Pharmacogenomic Variants , Retrospective Studies , Schizophrenia/blood , Young Adult
2.
Eur J Clin Pharmacol ; 72(2): 175-84, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26514968

ABSTRACT

PURPOSE: Therapeutic drug monitoring (TDM) of antipsychotics can aid in therapy optimization, explaining adverse effects or non-response. One reason for therapeutic failure or adverse effects is caused by genetic variations in the cytochrome P450 drug-metabolizing genes. The aim of this study was to evaluate the impact of CYP2D6 polymorphisms on steady-state serum concentrations of antipsychotics metabolized by CYP2D6, taking into account the co-medication with CYP2D6 inhibitors. METHODS: Serum and EDTA samples were collected from 82 psychiatric patients. After a liquid-liquid extraction, serum samples were analyzed using an ultra-high performance liquid chromatography-tandem mass spectrometric (UHPLC-MS/MS) method for quantification of the antipsychotics. CYP2D6 genotyping was performed using the Luminex xTAG® CYP2D6 Kit v3 (Luminex Corporation). Patients were divided into five phenotype subgroups by calculation of the activity score (AS): poor metabolizers (PM; AS 0), intermediate metabolizers (IM; AS 0.5-1), extensive metabolizers with slow activity (EM-s; AS 1-1.5), extensive metabolizers with fast activity (EM-f; AS 2), and ultra-rapid metabolizers (UM; AS >2). The influence of the phenotypes on the concentration-to-dose and metabolite-to-parent ratios was evaluated. RESULTS: Overall, 6.1 % UM (n = 5), 25.6 % EM-f (n = 21), 46.3 % EM-s (n = 38), 1.2 % EM-s/EM-f (n = 1), 6.1 % IM (n = 5), and 14.6 % PM (n = 12) were found, taking co-administration of strong and moderate CYP2D6 inhibitors into account (phenoconversion). It was demonstrated that CYP2D6 polymorphisms affect the serum concentrations of aripiprazole (n = 18), haloperidol (n = 11), risperidone (n = 20), and zuclopenthixol (n = 6), while no influence was seen on the paliperidone serum concentrations (n = 31). CONCLUSIONS: Even with a small number of patients per antipsychotic, the importance of CYP2D6 genotyping was still clearly stated. This study illustrates the high potential of combining TDM and CYP2D6 genotyping in clinical practice.


Subject(s)
Antipsychotic Agents , Aripiprazole , Clopenthixol , Cytochrome P-450 CYP2D6 , Haloperidol , Paliperidone Palmitate , Adult , Aged , Antipsychotic Agents/blood , Antipsychotic Agents/pharmacokinetics , Aripiprazole/blood , Aripiprazole/pharmacokinetics , Clopenthixol/blood , Clopenthixol/pharmacokinetics , Cytochrome P-450 CYP2D6/genetics , Cytochrome P-450 CYP2D6/metabolism , Drug Monitoring , Drug Therapy, Combination , Female , Genotype , Haloperidol/blood , Haloperidol/pharmacokinetics , Humans , Male , Middle Aged , Paliperidone Palmitate/blood , Paliperidone Palmitate/pharmacokinetics , Young Adult
4.
J Anal Toxicol ; 21(4): 314-8, 1997.
Article in English | MEDLINE | ID: mdl-9248952

ABSTRACT

A fatality that was due to massive ingestion of the thioxanthene neuroleptic (Z)-cis-clopenthixol (zuclopenthixol, Z-CPT) is described. The total toxicological screening and the quantitation of both the ingested drugs and its inactive isomer (E)-trans-clopenthixol (E-CPT, produced by in vivo isomerization) in postmortem fluids and viscerae were produced by high-performance liquid chromatography (HPLC)-diode array detection. Drug confirmation was carried out by HPLC-mass spectrometry with an ionspray interface. Although death occurred 40 h after the drug intake, postmortem blood concentrations were 391 and 275 mg/mL for Z-CPT and E-CPT, respectively (50 to 100 times the usual therapeutic values). The cause of death was suicide, and the manner was acute neuroleptic overdosage.


Subject(s)
Antipsychotic Agents/poisoning , Chromatography, High Pressure Liquid/methods , Clopenthixol/poisoning , Adolescent , Antipsychotic Agents/pharmacokinetics , Body Fluids/metabolism , Clopenthixol/pharmacokinetics , Drug Overdose , Fatal Outcome , Female , Humans , Mass Spectrometry , Tissue Distribution/physiology , Viscera/metabolism
6.
Ther Drug Monit ; 18(6): 629-34, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8946657

ABSTRACT

One hundred and nineteen psychiatric patients undergoing therapeutic drug monitoring (TDM) of the neuroleptic zuclopenthixol were genotyped with regard to Cyp2D6. Twelve patients (10.1%) were of the poor metabolizer genotype. The extensive metabolizers comprised 58 patients receiving no potentially interacting drugs and 38 patients concomitantly treated with other drugs competing for metabolism by Cyp2D6. Information on the rest (11 patients) was missing. The median steady-state serum concentration-to-dose ratio (C/D) of the PM group (2.00 nmol/L/mg) was close to that of the EM group receiving potentially interacting drugs (1.80) and approximately 60% higher than that of the remaining EM group (1.25) (p < 0.01). When judging the clinical importance of this difference, the total group variability in C/D of nearly 10-fold should be kept in mind (0.5-4.2 nmol/L/mg). In terms of serum concentrations not corrected for dose, the three groups had about similar levels, with median values from 16 to 21 nmol/L. We consider that TDM adequately takes into account dose adjustments for both EM and PM subjects in the context of this neuroleptic.


Subject(s)
Antipsychotic Agents/blood , Clopenthixol/blood , Cytochrome P-450 CYP2D6/genetics , Cytochrome P-450 CYP2D6/metabolism , Adolescent , Adult , Aged , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/pharmacokinetics , Clopenthixol/administration & dosage , Clopenthixol/pharmacokinetics , Denmark , Drug Interactions , Drug Monitoring , Female , Humans , Male , Mental Disorders/drug therapy , Mental Disorders/enzymology , Middle Aged , Polymorphism, Genetic
7.
Clin Pharmacol Ther ; 59(4): 423-8, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8612387

ABSTRACT

BACKGROUND: Most antidepressant and neuroleptic agents are metabolized by the polymorphic cytochrome P450 enzyme CYP2D6. This study evaluates the importance of the CYP2D6 genotype for the disposition of the neuroleptic agents perphenazine and zuclopenthixol. METHODS: Patients treated with neuroleptic agents (n = 36) were studied prospectively with regard to CYP2D6 genotype and neuroleptic plasma concentration during oral treatment. Because no patient provided enough samples for individual kinetic modeling, a bayesian approach was used for determination of the clearance. Population kinetic parameters for this procedure were collected from retrospective therapeutic drug monitoring data (n = 113) by use of a nonparametric approach. RESULTS: The CYP2D6 genotype significantly predicted the oral clearance of perphenazine and zuclopenthixol (p < 0.01 by multiple regression). The difference in clearance between homozygous extensive metabolizers and poor metabolizers was threefold for perphenazine and twofold for zuclopenthixol. CONCLUSION: The results show that the genotype for CYP2D6 is closely related to the oral clearances of perphenazine and zuclopenthixol. If this finding can be confirmed in a larger population, genotyping may become an important tool for the dosing of these two neuroleptic agents.


Subject(s)
Antipsychotic Agents/pharmacokinetics , Clopenthixol/pharmacokinetics , Cytochrome P-450 Enzyme System/genetics , Mixed Function Oxygenases/genetics , Perphenazine/pharmacokinetics , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Antipsychotic Agents/administration & dosage , Bayes Theorem , Clopenthixol/administration & dosage , Cytochrome P-450 CYP2D6 , Genotype , Humans , Middle Aged , Perphenazine/administration & dosage , Prospective Studies
8.
Ugeskr Laeger ; 155(32): 2443-8, 1993 Aug 09.
Article in Danish | MEDLINE | ID: mdl-8356762

ABSTRACT

The effect of therapeutic drug monitoring (TDM), including pharmacokinetic guidance, was examined in 994 psychiatric patients treated with perphenazine (Trilafon) or zuclopentixol (Cisordinol). Before monitoring of the serum level, half of the serum concentrations from patients given perphenazine tablets (466 patients) was below the therapeutic level, and about one third was above. For perphenazine depot (208 patients), almost no patients had a serum concentration below the therapeutic level whereas 40% had concentrations above. For zuclopentixol tablets (231 patienter) and zuclopentixol depot (163 patients), about 60% of the patients had concentrations above the therapeutic level. For all four groups, it was found that slightly more than half of the patients with serum concentrations outside the therapeutic level was reexamined. The dosage was changed in most of these patients (80-90%) in order to bring the concentration within the therapeutic level. Half of those in whom the dose was changed obtained concentrations within the therapeutic level. It is concluded that since the recommendations for changes of the dosage is followed to a wide extent, the therapeutic drug monitoring service does influence the treatment significantly.


Subject(s)
Clopenthixol/blood , Drug Monitoring , Mental Disorders/drug therapy , Perphenazine/blood , Clopenthixol/administration & dosage , Clopenthixol/pharmacokinetics , Delayed-Action Preparations , Humans , Mental Disorders/blood , Perphenazine/administration & dosage , Perphenazine/pharmacokinetics , Tablets
9.
Acta Psychiatr Scand ; 84(1): 99-102, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1927573

ABSTRACT

The pharmacokinetics of a single oral dose of the neuroleptic drug zuclopenthixol (10 or 6 mg) was studied in 6 extensive and 6 poor metabolizers of debrisoquine. The peak plasma concentrations of zuclopenthixol did not differ between the phenotypes, whereas the plasma elimination half-life was significantly longer in poor than in extensive metabolizers (29.9 +/- 6.6 vs 17.6 +/- 6.9 h). Accordingly, the total oral plasma clearance was lower in poor than in extensive metabolizers (0.78 +/- 0.27 vs 2.12 +/- 0.65 1/h/kg). Ten of the volunteers had previously participated in a similar study in which the kinetics of perphenazine, another neuroleptic drug, were studied in poor and in extensive metabolizers of debrisoquine. There was a significant correlation between the oral clearance of perphenazine and that of zuclopenthixol among these 10 subjects. The study indicates that the disposition of zuclopenthixol, as well as that of perphenazine, is related to the genetically determined capacity to hydroxylate debrisoquine. The significance of this polymorphism for the clinical use of neuroleptics is discussed.


Subject(s)
Clopenthixol/pharmacokinetics , Debrisoquin/metabolism , Administration, Oral , Adult , Clopenthixol/blood , Clopenthixol/therapeutic use , Debrisoquin/therapeutic use , Debrisoquin/urine , Female , Humans , Hydroxylation , Male , Perphenazine/metabolism , Perphenazine/therapeutic use , Schizophrenia/drug therapy
10.
Pharmacopsychiatry ; 22(6): 250-4, 1989 Nov.
Article in English | MEDLINE | ID: mdl-2575763

ABSTRACT

The purpose of the present study was to evaluate zuclopenthixol acetate in Viscoleo, a new preparation to be administered once every 3 days, in the early treatment of acute psychotic episodes and acute deterioration of chronic psychosis. 21 cases were included in the study: patients received 1 to 3 injections. Clinical evaluation was made at 24, 48 and 72 hours after each injection, using the Clinical Global Impressions (CGI) and the Brief Psychiatric Rating Scale (BPRS). Results at end-point indicated a marked or moderate therapeutic effect in the 11 cases of acute psychosis. A statistically significant decrease was observed for the total BPRS score as well as for its subscales. Among 8 cases of exacerbation of chronic psychosis, 4 patients showed a moderate therapeutic effect, and minimal or no effect was found in the other 4 subjects. The total BPRS decreased significantly, but to a lesser extent than for acute psychosis. Two patients suffering from mania showed a moderate therapeutic effect according to CGI. 8 cases of acute psychosis and 5 cases of chronic psychosis did not suffer from any neurological side-effects. Plasma concentration measurements suggest that a dose of 50 mg per 3 days may be sufficient for early treatment of most acutely ill psychotic patients.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Clopenthixol/therapeutic use , Psychotic Disorders/drug therapy , Thioxanthenes/therapeutic use , Adolescent , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Bipolar Disorder/psychology , Clopenthixol/adverse effects , Clopenthixol/analogs & derivatives , Clopenthixol/pharmacokinetics , Female , Humans , Male , Middle Aged , Parkinson Disease, Secondary/physiopathology , Psychiatric Status Rating Scales , Psychotic Disorders/psychology
11.
Article in English | MEDLINE | ID: mdl-2568662

ABSTRACT

1. The zuclopenthixol concentrations in serum has been investigated in man and dog after injection of three different zuclopenthixol preparations. These were zuclopenthixol dihydrochloride in aqueous solution, zuclopenthixol acetate in oil and zuclopenthixol decanoate in oil. 2. The pharmacokinetic profiles of the three injectable zuclopenthixol preparations are very different. Maximum serum levels are obtained after about 1 hour for zuclopenthixol dihydrochloride, after 36 hours for zuclopenthixol acetate and after one week for zuclopenthixol decanoate. 3. The different pharmacokinetics of the three injectable zuclopenthixol preparations are reflected in their clinical properties.


Subject(s)
Antipsychotic Agents/pharmacokinetics , Clopenthixol/pharmacokinetics , Psychotic Disorders/blood , Thioxanthenes/pharmacokinetics , Adult , Aged , Animals , Clopenthixol/administration & dosage , Clopenthixol/analogs & derivatives , Clopenthixol/therapeutic use , Dogs , Female , Humans , Injections, Intramuscular , Male , Middle Aged , Psychotic Disorders/drug therapy , Reference Values , Schizophrenia/blood , Schizophrenia/drug therapy
12.
APMIS ; 96(12): 1079-84, 1988 Dec.
Article in English | MEDLINE | ID: mdl-3214583

ABSTRACT

Some neuroleptic drugs of the phenothiazine and thioxanthene groups have an antimicrobial effect in vitro. This is also true for neuroleptically inactive stereo-isomeric analogs of the thioxanthenes e.g. trans(E)-clopenthixol (t-CPT). In a murine pneumococcus peritonitis model t-CPT demonstrated a slight, but non-significant antibacterial effect in doses of 0.3-0.9 mg per mouse, while higher doses seemed to enhance the bacterial virulence. If combined with subtherapeutic doses of penicillin, a significantly higher survival rate was obtained compared with either drug given alone. In vitro studies demonstrated a similar synergistic effect. These results indicate that at least one non-neuroleptic thioxanthene stereo-isomer has an antibiotic potential also in vivo. The mechanism of action is not known.


Subject(s)
Clopenthixol/administration & dosage , Penicillins/administration & dosage , Pneumococcal Infections/drug therapy , Thioxanthenes/administration & dosage , Animals , Clopenthixol/pharmacokinetics , Dose-Response Relationship, Drug , Drug Synergism , Mice , Microbial Sensitivity Tests , Stereoisomerism , Streptococcus pneumoniae/drug effects
13.
APMIS ; 96(4): 357-60, 1988 Apr.
Article in English | MEDLINE | ID: mdl-3285868

ABSTRACT

Previous in vitro studies have shown suppression of the growth of Plasmodium falciparum by the neuroleptic agents chlorpromazine and zuclopenthixol (formerly known as cis(Z)-clopenthixol) as well as by the neuroleptic inactive steroisomer trans(E)-clopenthixol. These compounds are chemically related to riboflavin and may act as inhibitors of riboflavin metabolism. As trans(E)-clopenthixol has been found active against chloroquine-resistant strains of P. falciparum in vitro and has been approved for human use, though inactive as a neuroleptic, this drug was selected for the present in vivo study. The dosage of trans(E)-clopenthixol was optimized through a pharmacokinetic study, and the suppression of the growth of Plasmodium berghei in vivo was tested in mice, with chloroquine acting as the positive and saline as the negative control. Trans(E)-clopenthixol did not inhibit the growth of P. berghei, whereas chloroquine almost eradicated the infection. The use of in vitro screening for anti-malarial activity in drugs approved for human use for other indications is discussed in the light of the results. It is concluded that the selection of drugs for further studies in vivo cannot solely be based on positive results in vitro.


Subject(s)
Clopenthixol/therapeutic use , Malaria/drug therapy , Plasmodium berghei/drug effects , Thioxanthenes/therapeutic use , Animals , Chloroquine/pharmacology , Chloroquine/therapeutic use , Clopenthixol/analogs & derivatives , Clopenthixol/pharmacokinetics , Clopenthixol/pharmacology , Female , Malaria/parasitology , Mice , Plasmodium berghei/growth & development
14.
Psychopharmacology (Berl) ; 94(3): 293-7, 1988.
Article in English | MEDLINE | ID: mdl-2895936

ABSTRACT

Seventeen outpatients were treated with depot neuroleptics, zuclopenthixol decanoate in Viscoleo or fluphenazine decanoate in sesame oil, with dosage intervals of 3 weeks. During the 4th, 6th, and 8th dosage interval blood samples were drawn in oxalated tubes. Plasma concentrations of the active neuroleptic drugs, zuclopenthixol and fluphenazine, were determined by high performance liquid chromatography. The concentrations indicated some interindividual as well as intraindividual variations. For zuclopenthixol the maximum concentration was most often seen at day 7 after injection, whereas the kinetics of the fluphenazine concentrations was more variable. There was an indication of more fluctuation in the 4th dosage interval than in the 8th dosage interval, possibly due to the fact that steady state has not yet been achieved at the 4th dosage interval.


Subject(s)
Antipsychotic Agents/pharmacokinetics , Clopenthixol/pharmacokinetics , Fluphenazine/analogs & derivatives , Thioxanthenes/pharmacokinetics , Tranquilizing Agents/pharmacokinetics , Adult , Antipsychotic Agents/therapeutic use , Clopenthixol/analogs & derivatives , Clopenthixol/therapeutic use , Female , Fluphenazine/pharmacokinetics , Fluphenazine/therapeutic use , Humans , Male , Middle Aged , Schizophrenia/drug therapy , Tranquilizing Agents/therapeutic use
15.
Drug Nutr Interact ; 5(3): 157-60, 1987.
Article in English | MEDLINE | ID: mdl-3691322

ABSTRACT

The single-dose kinetics of the neuroleptic thioxanthene zuclopenthixol was assessed in 12 healthy volunteers who ingested 10 mg of the drug orally, both on an empty stomach and together with a standardized breakfast of 1840 kj (440 kcal). The serum concentrations of zuclopenthixol were measured by HPLC. Concomitant food intake did not influence the peak concentration nor the time to reach the peak concentration or the elimination half-life of zuclopenthixol, but the AUC values were significantly increased. Hence it seems likely that concomitant food intake enhances the bioavailability of zuclopenthixol, without influencing its absorption rate. The most likely mechanism is that food reduces the presystemic clearance of the drug. As the increase in AUC was only 26%, it is doubtful whether zuclopenthixol has to be administered in a standardized relation to meals.


Subject(s)
Clopenthixol/pharmacokinetics , Food , Thioxanthenes/pharmacokinetics , Adult , Biological Availability , Clopenthixol/blood , Female , Half-Life , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...